Cardiology

Back to articles

Biomarker-guided therapy in heart failure no better than routine care

KEY POINT

Results of the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated no difference in clinical outcomes for high-risk patients with heart failure (HF) and reduced ejection fraction (HFrEF) who were treated with biomarker-guided therapy to obtain N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of less than 1,000 pg/mL compared with those treated with guideline-recommended medical care.